LETTER TO THE EDITOR

An update on choroidal abnormalities and retinal microvascular changes in neurofibromatosis type 1

Fabiana Mallone1, Luca Lucchino1, Sandra Giustini2, Alessandro Lambiase1* and Antonietta Moramarco1

Abstract
Neurofibromatosis Type 1 (NF1) is a rare neurocutaneous disorder transmitted in an autosomal dominant fashion, mainly affecting the nervous system, the eye and skin. Ocular diagnostic hallmarks of NF1 include iris Lisch nodules, optic gliomas, orbital and eyelid neurofibromas, eyelid café-au-lait spots. In recent years, a new ocular sign represented by choroidal abnormalities (CAs) has been characterized in NF1. The CAs, identified with near-infrared reflectance, have been reported with a frequency of up to 100% in NF1, and have recently been added to the actual diagnostic criteria for NF1. The present Letter to the journal is intended to provide an update on features and clinical significance of CAs in NF1. Moreover, the relation with other ocular manifestations recently described in NF1 including hyperpigmented spots and retinal microvascular abnormalities is discussed.

Keywords: Choroidal abnormalities (CAs), Neurofibromatosis type 1 (NF1), Diagnostic criteria, Hyperpigmented spots (HSs), Retinal microvascular abnormalities (RVAs)

Dear Editor,
Neurofibromatosis type 1 (NF1), also termed von Recklinghausen disease, is a rare autosomal dominant multisystemic disorder, with complete penetrance and variable expressivity. It is caused by a mutation in the NF1 gene located on chromosome 17q11.2 that encodes for neurofibromin, a protein that controls cell growth and proliferation by regulating the proto-oncogene Ras; and it is 50% sporadic or inherited. The pathogenesis of NF1 involves neural crest-derived melanocytes, Schwann cells, prevertebral ganglion and sympathetic neurons. The disease can affect nearly all organ systems in the body. NF1 main characteristics are the appearance of various cutaneous, ocular and neurological manifestations, and an increased susceptibility to develop multiple benign and malignant tumors.

The disease can also present as mosaicism, also called segmental NF1. In these cases, NF1 preserves the usual characteristics but is localized only in a body segment.

The eye and adnexa are frequently involved in NF1; some ocular manifestations including iris Lisch nodules, optic gliomas, orbital and eyelid neurofibromas, eyelid café-au-lait spots, are diagnostic hallmarks in NF1.

In the last years, new manifestations including choroidal abnormalities (CAs), hyperpigmented spots (HSs) and retinal vascular abnormalities (RVAs), have been described in the ocular system in NF1, due to recent progress in multimodal imaging in ophthalmology (Figs. 1, 2, 3) [1–7].

Following a revision by an international consensus of experts, CAs have recently been added to the actual diagnostic criteria for NF1 based on their high specificity and sensitivity [8]. Furthermore, the presence of CAs allows to differentiate NF1 from Legius syndrome, which shows phenotypic overlap to NF1 [8, 9].
In the revised diagnostic criteria for NF1, CAs are not included as a separate criterion, but rather introduced as an alternative to the presence of iris Lisch nodules since isolated ophthalmologic findings, even if bilateral, are likely to reflect mosaic NF1 rather than constitutional NF1 [8]. Specifically, the patient is assigned 1 diagnostic criteria point in the presence of both CAs and iris Lisch nodules but he is still assigned 1 diagnostic criteria point also in the presence of either CAs or iris Lisch nodules. This is to avoid that, in the presence of both CAs and iris Lisch nodules, the patient is assigned 2 diagnostic criteria points and a diagnosis of NF1 is made, when there exists a possibility for it to be segmental NF1 [8].

CAs are known as ovoid bodies consisting of proliferating Schwann cells, neural crest-derived melanocytes and ganglion cells around axons arranged in lamellar patterns [10, 11]. Based on these features, CAs were attributed to hamartomatous lesions similar to the iris Lisch nodules, both showing the same embryological origin from the neural crest [12].

In previous studies, CAs were reported having higher prevalence (64–98%) in NF1 compared to iris Lisch nodules (41–86%), the latter considered to date the most frequent diagnostic ocular sign in NF1 [2, 3, 13–16]. Notably, the frequency of manifestation of approximately 100% of CAs is similar or second only to café-au-lait spots (98%), the most frequent diagnostic criterion in NF1 [2, 13, 14, 17]. In addition, CAs showed earlier age of presentation in NF1 compared to iris Lisch nodules with reported percentages of 64–95% and 41–52%, respectively, in the pediatric population [2, 13–16]. Furthermore, higher percentages (14–37%) of patients with NF1 were reported to have CAs but no iris Lisch nodules, while only a few patients (2.5–16%) had iris Lisch nodules in the absence of CAs [2, 13, 14, 16].
These observations may suggest that CAs are of higher diagnostic importance than iris Lisch nodules and support the inclusion of both CAs and iris Lisch nodules as relevant signs in the revised diagnostic criteria for NF1.

In the CAs, the proliferation of choroidal cell types causes a patchy choroidal thickening, resulting in a strong absorption and a subsequent backscattering of near-infrared light through the high content of melanin.

Recently, the spectral domain optical coherence tomography (SD-OCT) in near-infrared reflectance (NIR) modality, a non-invasive tool, has enabled superior visibility of CAs. Specifically, CAs appear as bright, patchy nodules on SD-OCT in NIR mode.

CAs are fully asymptomatic and undetectable with conventional ophthalmoscopic examination or by means of autofluorescence and fluorescein angiography. Indocyanine green angiography, at a wavelength similar to that of NIR, proved to be helpful in recording hypofluorescent patches corresponding to CAs in NF1, but it is an invasive diagnostic tool.

The hyperreflectivity of the CAs on NIR-OCT is attributable to a hyperactivity of the melanosomes and/or to an increase in the number of melanocytes in the choroid [18].

In agreement, CAs were reported to have predominant distribution within the main vascular arcades, based on greater thickness of the choroid and higher proportion of melanocytes in this area [19].

More recently, optical coherence tomography angiography (OCTA) studies demonstrated hyper-flow areas of deep choroid corresponding to the bright patches of CAs on NIR imaging [20].

Recent findings from our group reported that CAs may have different level of extension in the deeper choroid and different degree of pigmentation, reaching the level of visibility at fundus examination only in a minority of cases [3]. Specifically, as assessed through different wavelengths on ultra-wide field (UWF) scanning laser ophthalmoscopy and SD-OCT imaging, the most pigmented and inward extended CAs were visible as HSs at fundus examination, representing a new finding in NF1 [3].

This explains the different frequency of presentation of CAs and HSs, showing percentages of nearly 97% versus 24%, respectively, from our previous studies [3]. HSs appear as rounded, hyperpigmented areas with blurred margins at color fundus photography, with predominant distribution to the posterior pole similar to CAs location [3].

CAs are widely regarded as purely morphological alterations, which do not cause sensory abnormalities [2, 21]. However, their effect on surrounding retino-choroidal vasculature is yet to be established.

Interestingly, our group reported the association between HSs and NF1-related RVAs [3]. Also, previous studies investigated the relationship between CAs and overlying retinal microvascular changes in patients with NF1 [22].

RVAs, well-defined, small, tortuous retinal vessels arising from small tributaries of the retinal veins, constitute an ocular feature of recent observation in NF1 [1, 23]. Three different vascular patterns, ranging from a simple involvement to more complex manifestations, are known in literature: simple vascular tortuosity, corkscrew retinal vessels’ configuration and finally the moyamoya-like appearance [1].

In all cases, abnormal vessels occur in the superficial vascular plexus (SCP) from OCTA studies, with associated crowded and congested capillary network of the deep vascular plexus in the majority of cases [23, 24]. Similar to CAs and HSs, RVAs are mainly reported at the posterior pole [1].

Recently, a topographical correspondence has been described between CAs and overlying corkscrew retinal vessels, with debate on different pathogenetic hypotheses [22, 25]. It was speculated that the development of RVAs could possibly be related to disease-related disorders of vasomotor nerve cells or secretion of angiogenic factors by the CAs in NF1 patients [22, 25]. Results from OCTA studies limited to case series, reported abnormal retinal vessels overlying CAs with low flow areas and reduced vessel density at the level of choriocapillaris in NF1 [20, 26].

In a case–control study, the group of Vagge et al. reported a significant increase in the vascular flow area of the SCP and associated reduced choroidal vascular flow area in patients with NF1. These findings were attributed to a pathological redistribution of the vascular flow caused by the presence of CAs [27].

The results from these studies support the hypothesis that CAs compression and related blood flow redistribution could possibly have a role in the development of RVAs, however, this needs to be clarified in further work.

In conclusion, this Letter to the journal aims to provide insights on the features and clinical significance of CAs, a new diagnostic criterion for NF1, and emphasizes the importance for physicians of obtaining SD-OCT NIR imaging when evaluating patients with suspected NF1 in the clinic. Moreover, the strict relation between CAs and other ocular manifestations recently described in NF1 including HSs and RVAs was discussed. These new findings highlight the relevance of ocular involvement in NF1 disease, and this is expected to encourage further efforts in this field of clinical research.
Acknowledgements
Not applicable.

Author contributions
FM, JL and AM conceived and wrote the Letter. FM and JL contributed to the acquisition of data. AL and SG conceived of the study and critically evaluated the accuracy and integrity of the work. All authors contributed to refinement of the study and approved the final manuscript. This manuscript has been read and approved by all the authors and each author believes that the manuscript represents honest work. All authors meet the requirements for authorship and all express full consent for publication on your esteemed Journal. All authors read and approved the final manuscript.

Funding
No financial support has been requested for the study.

Availability of data and materials
The data used to support the findings of this study are available from the corresponding author upon request.

Declarations
Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee of Sapienza University of Rome and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants in the study.

Consent for publication
Informed consent to publish personal or clinical details along with any identifying images was obtained from study patients.

Competing interests
All authors certify that they have no financial or proprietary interest in the subject matter or materials discussed in this manuscript. The authors declare that they do not have any conflicts or potential competing interests.

Author details
1 Department of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Viale del Policlinico 155, 00161 Rome, Italy. 2 Department of Dermatology and Venerology, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy.

Received: 26 October 2021 Accepted: 29 May 2022
Published online: 13 June 2022

References
1. Moramarco A, Miraglia E, Mallone F, Roberti V, Iacovino C, Bruscolini A, et al. Retinal microvascular abnormalities in neurofibromatosis type 1. Br J Ophthalmol. 2019;103:1500–4.
2. Moramarco A, Giustini S, Nofroni I, Mallone F, Miraglia E, Iacovino C, et al. Near-infrared imaging: an in vivo, non-invasive diagnostic tool in neurofibromatosis type 1. Graefes Arch Clin Exp Ophthalmol. 2018;256:307–11.
3. Moramarco A, Mallone F, Sacchetti M, Lucchino L, Miraglia E, Roberti V, et al. Hyperpigmented spots at fundus examination: a new oculic sign in Neurofibromatosis Type I. Orphanet J Rare Dis. 2021;16:1–9.
4. Moramarco A, Sacchetti M, Franzone F, Segatto M, Cecchetti D, Miraglia E, et al. Ocular surface involvement in patients with neurofibromatosis type 1 syndrome. Graefes Arch Clin Exp Ophthalmol. 2020;258:1757–62.
5. Nebbioso M, Moramarco A, Lambiase A, Giustini S, Marconi M, Miraglia E, et al. Neurofibromatosis type 1: Ocular electrophysiological and perimetric abnormalities. Eye Brain. 2020;12:119–27.
6. Moramarco A, Lambiase A, Mallone F, Miraglia E, Giustini S. A characteristic type of retinal microvascular abnormalities in a patient with Neurofibromatosis type 1. Clin Ter. 2019;170:E4–9.
7. Moramarco A, Giustini S, Miraglia E, Lambiase A, Sacchetti M. SD-OCT in NIR modality to diagnose retinal microvascular abnormalities in neurofibromatosis type 1. Graefes Arch Clin Exp Ophthalmol. 2018;256:1789–90.
8. Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021;23:1506–13.
9. Tucci A, Saletti V, Menni F, Cesaretti C, Scuvera G, Esposito S, et al. The absence that makes the difference: choroidal abnormalities in Legius syndrome. J Hum Genet. 2017;62:1001–4.
10. Kurosawa A, Kurosawa H. Ovoid bodies in choroidal neurofibromatosis. Arch Ophthalmol. 1982;100:1399–41.
11. Wolter JR. Nerve fibrils in ovoid bodies: with neurofibromatosis of the choroid. Arch Ophthalmol. 1965;73:696–9.
12. Wallace MR. Neurofibromatosis: phenotype, natural history, and pathogenesis. Am J Hum Genet. 2000;67:264.
13. Viola F, Villani E, Natacci F, Seilicorni A, Ophthalmogamy GM, undefined. Choroidal abnormalities detected by near-infrared reflectance imaging as a new diagnostic criterion for neurofibromatosis type 1. Ophthalmology. 2012;119:369–75.
14. Vagge A, Camicione P, Capris C, Sburlati C, Panarello S, Galevo MG, et al. Choroidal abnormalities in neurofibromatosis type 1 detected by near-infrared reflectance imaging in paediatric population. Acta Ophthalmol. 2015;93:e667–71.
15. Goktas S, Sakarya Y, Ozcinem M, Alfpidan I, Uzun M, Sakarya R, et al. Frequency of choroidal abnormalities in pediatric patients with neurofibromatosis type 1. J Pediatr Ophthalmol Strabismus. 2014;51:204–8.
16. Pinmentel MF, Heath A, Wan MJ, Husseen R, Leahy KE, Macdonald H, et al. Prevalence of choroidal abnormalities and Ishikawa nodes in children meeting clinical and molecular diagnosis of neurofibromatosis type 1. Transl Vis Sci Technol. 2022;11:10.
17. Miraglia E, Moliterni E, Iacovino C, Roberti V, Laghi A, Moramarco A, et al. Cutaneous manifestations in neurofibromatosis type 1. Clin Ter. 2020;171:e371–7.
18. Ueda-Consolvo T, Miyakoshi A, Ozaki H, Houki S, Hayashi A. Near-infrared fundus autofluorescence-visualized melanin in the choroidal abnormalities of neurofibromatosis type 1. Clin Ophthalmol. 2012;6:1191–4.
19. Nakakura S, Shiraiki K, Yasunari T, Hayashi Y, Ataka S, Kohno T. Quantification and anatomic distribution of choroidal abnormalities in patients with type I neurofibromatosis. Graefe’s Arch Clin Exp Ophthalmol. 2005;243:982–4.
20. Kumar V, Singh S. Multimodal imaging of choroidal nodules in neurofibromatosis type-1. Indian J Ophthalmol. 2018;66:586.
21. Klein RM, Glassman L. Neurofibromatosis of the choroid. Am J Ophthalmol. 1985;99:367–8.
22. Abdolrahimzadeh S, Felli L, Piraino DC, Mollo R, Calvieri S, Recupero SM. Retinal microvascular abnormalities overlying choroidal nodules in neurofibromatosis type 1. BMC Ophthalmol. 2014;14:146.
23. Parrozzani R,获批lo E, Clementi M, Frizziero L, Leonardi F, Corvento E, et al. Retinal vascular abnormalities in a large cohort of patients affected by neurofibromatosis type 1: a study using optical coherence tomography angiography. Retina. 2018;38:585–93.
24. Abdolrahimzadeh S, Felli L, Piraino DC, Calvieri S, Recupero SM. Retinal microvascular abnormalities overlying choroidal nodules in neurofibromatosis type 1. BMC Ophthalmol. 2014;14:146.
25. Parrozzani R,获批lo E, Clementi M, Frizziero L, Leonardi F, Corvento E, et al. Retinal vascular abnormalities related to neurofibromatosis type 1: a natural history and classification by OCT angiography in 473 patients. Retina. 2021;41:979–86.
26. Cassim C, Casteels I, Stalman P, Legius E, Jacob J. Optical coherence tomography angiography of retinal microvascular changes overlying choroidal nodules in neurofibromatosis type 1. Case Rep Ophthalmol. 2017;8:214–20.
27. Moreno-Morillo FJ, Fernández-Vigo JI, Burgos-Blasco B, Llorente-La Orden C, Vilad-Villegas B, Santos-Bueso E. Optical coherence tomography angiography of choroidal nodules in neurofibromatosis type 1: a case series. Eur J Ophthalmol. 2021. https://doi.org/10.1177/11206721211030781.
28. Vagge A, Corazza P, Desideri L, Camicione P, Agostino G, Vagge R, et al. Ocular biometric parameters changes and choroidal vascular abnormalities in patients with neurofibromatosis type 1 evaluated by OCT-A. PLoS ONE. 2021. https://doi.org/10.1371/journal.pone.0251098.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.